Understanding how JAK inhibitors may increase blood clot risk

Why do medications that are supposed to help patients with chronic inflammatory diseases sometimes lead to blood clots?

EMA recommends suspension of 17-OHPC medicines in the EU

In some EU countries, 17-OHPC medicines have been authorised as injections for preventing pregnancy loss or premature birth. Credit: Victoria Moloman / Shutterstock.com. The European

May 20, 2024

(Azacitidine + cedazuridine) by Taiho Oncology for Myelodysplastic Syndrome: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

December 29, 2024

Bayer’s promising menopause drug trial results highlight growing interest in long-neglected condition

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant

January 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.